Wu, Guangyao
Jochems, Arthur
Refaee, Turkey
Ibrahim, Abdalla
Yan, Chenggong
Sanduleanu, Sebastian
Woodruff, Henry C.
Lambin, Philippe
Funding for this research was provided by:
European Research Council (ERC-ADG-2015, n° 694812)
H2020 European Research Council (ImmunoSABR - n° 733008;PREDICT - ITN - n° 766276;CHAIMELEON - n° 952172)
Article History
Received: 23 November 2020
Accepted: 3 February 2021
First Online: 11 March 2021
Declarations
:
: This article does not contain any studies with human participants or animals performed by any of the authors.
: P. Lambin reports, outside the submitted work, minority shares in The Medical Cloud Company and grants/sponsored research agreements from Varian medical, Oncoradiomics, ptTheragnostic/DNAmito and, Health Innovation Ventures. P. Lambin received an advisor/presenter fee and/or reimbursement of travel costs/external grant writing fee and/or in kind man-power contribution from Oncoradiomics, BHV, Varian, Elekta, ptTheragnostic and Convert pharmaceuticals. P. Lambin has shares in the company Oncoradiomics SA, Convert pharmaceuticals SA and is co-inventor of two issued patents with royalties on radiomics (PCT/NL2014/050248, PCT/NL2014/050728) licensed to Oncoradiomics and one issued patent on mtDNA (PCT/EP2014/059089) licensed to ptTheragnostic/DNAmito, three non-patented invention (softwares) licensed to ptTheragnostic/DNAmito, Oncoradiomics and Health Innovation Ventures and three non-issues, non-licensed patents on Deep Learning-Radiomics and LSRT (N2024482, N2024889, N2024889). H.C. Woodruff owns shares in Oncoradiomics, outside the submitted work. G. Wu, A. Jochems, T. Refaee, A. Ibrahim, C. Yan, and S. Sanduleanu declare that they have no conflict of interest.